Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results
Incyte Corp. (INCY) reported strong Q2 results, raised full-year sales guidance. CEO cites sales growth, pipeline progress, and business development. Analysts maintain buy ratings with price target increases.
Incyte had a great quarter, so people who study the company think it will make more money this year than they thought before. This tells us the company's medicines are selling well and new ones are coming, which are signs of a healthy business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.